15.76
+0.11(+0.70%)
Currency In USD
| Previous Close | 15.65 |
| Open | 15.76 |
| Day High | 15.85 |
| Day Low | 15.62 |
| 52-Week High | 72.37 |
| 52-Week Low | 9.12 |
| Volume | 226,377 |
| Average Volume | 457,814 |
| Market Cap | 640.1M |
| PE | 49.25 |
| EPS | 0.32 |
| Moving Average 50 Days | 14.54 |
| Moving Average 200 Days | 16.81 |
| Change | 0.11 |
If you invested $1000 in Keros Therapeutics, Inc. (KROS) since IPO date, it would be worth $784.86 as of September 12, 2025 at a share price of $15.76. Whereas If you bought $1000 worth of Keros Therapeutics, Inc. (KROS) shares 3 years ago, it would be worth $395.58 as of September 12, 2025 at a share price of $15.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with d
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Aug 20, 2025 1:48 PM GMT
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with di
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
GlobeNewswire Inc.
Aug 06, 2025 8:15 PM GMT
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutic